Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 09 04 2021
revised: 04 06 2021
accepted: 22 06 2021
pubmed: 18 10 2021
medline: 18 3 2022
entrez: 17 10 2021
Statut: ppublish

Résumé

Since MELD implementation renal impairment in liver transplant (LT) recipients has become of increasing importance. This is the first study evaluating the course of renal function immediately prior to LT as predictor for long-term renal and overall outcome. In this retrospective study, 226 adults undergoing LT at the University Medical Center Hamburg-Eppendorf (2011-2015) were included. The impact of renal function over a period of 3 months prior to LT compared to renal function at the day of LT on long-term renal outcome and survival was assessed. According to GFR at day of LT renal function improved (≥1 CKD stage) in 64 patients (28%), remained stable in 144 (64%) or deteriorated in 18 (8%). Improvement of renal function prior to LT did neither significantly affect 90-day (13% vs. 14%, p = 0.83), nor 5-year post-LT mortality (35% vs. 41%, p = 0.57). 50 patients (22%) with hepatorenal syndrome (HRS) received terlipressin prior to LT, but only 18 (37%) showed prolonged stabilization of renal function (improvement ≥1 CKD stage). Response to terlipressin did neither improve 90-day (p=1), 5-year mortality (p = 0.52) nor long-term renal function (p = 0.843). Nevertheless, need for dialysis pre-LT (59% vs. 34%, p = 0.005) and post-LT (62% vs. 17%, p<0.001) was associated with increased 5-year mortality. Improvement of renal function immediately prior to LT, either spontaneously or following terlipressin therapy, did neither ameliorate long-term renal outcome nor survival in LT recipients. Future studies need to clarify the impact of terlipressin in HRS on the transplant waiting time in LT candidates.

Identifiants

pubmed: 34656773
pii: S1665-2681(21)00258-1
doi: 10.1016/j.aohep.2021.100559
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

100559

Informations de copyright

Copyright © 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare that they have no conflict of interest.

Auteurs

Thomas Horvatits (T)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: t.horvatits@uke.de.

Peter Hübener (P)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Marcel Touma (M)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Karoline Horvatits (K)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lutz Fischer (L)

Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ansgar W Lohse (AW)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Martina Sterneck (M)

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH